A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 1, 2013, Pages 60-65

  Fu, Zhenyan ^a   Ma, Yitong ^a   Xie, Xiang ^a   Huang, Ding ^a   Yang, Hong ^a   Nakayama, Tomohiro ^b   Sato, Naoyuki ^b  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

case control study; CYP4A11; single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 4AII; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; CORONARY ARTERY DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84871540343     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611436197     Document Type: Article

References (37)

1. Frazier L, Johnson RL, Sparks E. Genomics and cardiovascular disease. J Nurs Scholarsh. 2005 ; 37 (4). 315-321
2. Nordlie MA, Wold LE, Kloner RA. Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol. 2005 ; 39 (4). 667-679
3. Winkelmann BR, Hager J. Genetic variation in coronary heart disease and myocardial infarction: methodological overview and clinical evidence. Pharmacogenomics. 2000 ; 1 (1). 73-94
4. Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther. 2010 ; 125 (3). 446-463
5. Elbekai RH, El-Kadi AO. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther. 2006 ; 112 (2). 564-587
6. Wang XL, Greco M, Sim AS, Duarte N, Wang J, Wilcken DE. Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis. 2002 ; 162 (2). 391-397
7. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet. 2004 ; 41 (10). 758-762
8. Yasar U, Bennet AM, Eliasson E, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003 ; 13 (12). 715-720
9. Funk M, Endler G, Freitag R, et al. CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. Clin Chem. 2004 ; 50 (12). 2395-2398
10. Spiecker M, Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004 ; 110 (15). 2132-2136
11. Nakayama T, Soma M, Saito S, et al. Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction. Am Heart J. 2002 ; 143 (5). 797-801
12. Hengstenberg C, Holmer SR, Mayer B, et al. Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction. Hypertension. 2000 ; 35 (3). 704-709
13. Letonja M, Peterlin B, Bregar D, et al. Are the T/C polymorphism of the CYP17 gene and the tetranucleotide repeat (TTTA) polymorphism of the CYP19 gene genetic markers for premature coronary artery disease in Caucasians?. Folia Biol (Praha). 2005 ; 51(3): 76-81
14. Gainer JV, Bellamine A, Dawson EP, et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation. 2005 ; 111 (1). 63-69
15. Mayer B, Lieb W, Götz A, et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension. 2005 ; 46 (4). 766-771
16. Muthalif MM, Benter IF, Karzoun N, et al. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci U.S.A. 1998 ; 95 (21). 12701-12706
17. Fu Z, Nakayama T, Sato N, et al. Haplotype-based case study of human CYP4A11 gene and cerebral infarction in Japanese subject. Endocrine. 2008 ; 33 (2). 215-222
18. Uddin MR, Muthalif MM, Karzoun NA, et al. Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling. Hypertension. 1998 ; 31 (2). 242-247
19. Muthalif MM, Karzoun NA, Gaber L, et al. Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension. 2000 ; 36 (4). 604-609
20. Vazquez B, Rios A, Escalante B. Arachidonic acid metabolism modulates vasopressin-induced renal vasoconstriction. Life Sci. 1995 ; 56 (18). 1455-1466
21. Chu ZM, Croft KD, Kingsbury DA, Falck JR, Reddy KM, Beilin LJ. Cytochrome P450 metabolites of arachidonic acid may be important mediators in angiotensin II-induced vasoconstriction in the rat mesentery in vivo. Clin Sci (Lond). 2000 ; 98 (3). 277-282
22. Imig JD, Pham BT, LeBlanc EA, Reddy KM, Falck JR, Inscho EW. Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension. 2000 ; 35 (1 pt 2). 307-312
23. Schwartzman ML, Abraham NG, Masferrer J, et al. Cytochrome P450 dependent metabolism of arachidonic acid in bovine corneal epithelium. Biochem Biophys Res Commun. 1985 ; 132 (1). 343-351
24. Quigley R, Baum M, Reddy KM, et al. Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am J Physiol Renal Physiol. 2000 ; 278 (6). 949-953
25. McGiff JC, Quilley J. 20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr Opin Nephrol Hypertens. 2001 ; 10 (2). 231-237
26. Hill E, Fitzpatrick F, Murphy RC. Biological activity and metabolism of 20-hydroxyeicosatetraenoic acid in the human platelet. Br J Pharmacol. 1992 ; 106 (2). 267-274
27. Gross GJ, Falck JR, Gross ER, et al. Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc Res. 2005 ; 68 (1). 18-25
28. Nithipatikom K, Gross ER, Endsley MP, et al. Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res. 2004 ; 95 (8). e65 - e71
29. Lino Cardenas CL, Renault N, Farce A, et al. Genetic polymorphism of CYP4A11 and CYP4A22 genes and in silico insights from comparative 3D modelling in a French population. Gene. 2011 ; 487 (1). 10-20
30. Laffer CL, Gainer JV, Waterman MR, et al. The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension. 2008 ; 51 (3). 767-772
31. Fava C, Montagnana M, Almgren P, et al. The V433 M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension. 2008 ; 52 (2). 373-380
32. Williams JS, Hopkins PN, Jeunemaitre X, Brown NJ. CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow. J Hypertens. 2011 ; 29 (10). 1913-1918
33. Ward NC, Tsai IJ, Barden A, et al. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension. 2008 ; 51 (5). 1393-1398
34. Sugimoto K, Akasaka H, Katsuya T, et al. A polymorphism regulates CYP4A11 transcriptional activity and is associated with hypertension in a Japanese population. Hypertension. 2008 ; 52 (6). 1142-1148
35. Hermann M, Hellermann JP, Quitzau K, et al. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease - the ENCORE trials. Atherosclerosis. 2009 ; 207 (2). 476-479
36. Mayer B, Lieb W, Götz A, et al. Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens. 2006 ; 24 (10). 1965-1970
37. Zhang R, Lu J, Hu C, et al. A common polymorphism of CYP4A11 is associated with blood pressure in a Chinese population. Hypertens Res. 2011 ; 34 (5). 645-648